Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Results 1-25 of 208 for your search:
Start Over
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 22 and over
Trial IDs: EF-19, NCI-2013-00553, NCT01756729
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Phase: Phase IV
Type: Diagnostic
Age: 18 and over
Trial IDs: DGD-44-058, NCI-2015-00294, NCT02034708
Perampanel in Lowering the Incidence of Seizures in Patients with Primary Glioma
Phase: Phase IV
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00055609, NCI-2015-00365, NCT02363933
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Radiation Therapy with or without Temozolomide in Treating Patients with Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0834, NCI-2011-02070, CAN-NCIC-CEC1, CDR0000582632, COGNO-EORTC-26053, EORTC-22054, EORTC-26053, EUDRACT-2006-001533-17, MERCK-EORTC-26053, MRC-BR14, SPRI-EORTC-26053, CEC1, NCT00626990
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Armodafinil in Reducing Cancer-Related Fatigue in Patients with High-Grade Glioma
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: A221101, NCI-2012-02020, N10C3, NCT01781468
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 021-003, NCI-2010-01643, NCT00394628
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Fluorothymidine F 18-Labeled Positron Emission Tomography in Finding Recurrent Disease in Patients With Primary Brain Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI20112, NCI-2010-00958, NCT00707343
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Temozolomide and Hypofractionated Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BRN0012, NCI-2011-00043, SU-04202010-5726, NCT01120639
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-122, NCI-2011-01164, NCT01260506
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: DLM-10-001, NCI-2014-00140, NCT01478178
Start Over